Find information on thousands of medical conditions and prescription drugs.

Chlorpropamide

Chlorpropamide is a sulphonylurea drug used to treat type 2 diabetes mellitus. Its renal clearance and long half-life cause hypoglycemia as a side-effect more frequently than newer sulphonylureas.

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


EASD conference round-up: … news from Munich, 5th—8th September 2004
From Journal of Diabetes Nursing, 10/1/04

PLENARY LECTURE

DIGAMI 2: A randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: Effects on mortality at 1 year. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L

DIGAMI 2 included a total of 1253 patients with suspected acute myocardial infarction (AMI) from 48 hospitals in Europe. Patients were randomised to one of three groups: (1) acute insulin-glucose infusion followed by insulin-based long-term glucose control (474 patients); (2) insulin-glucose infusion followed by standard glucose control (i.e., no insulin) (473 patients); or (3) routine metabolic management according to local practice (306 patients).

The primary endpoint was all-cause mortality between groups 1 and 2 according to intention-to-treat analysis, while mortality differences between groups 2 and 3 and morbidity differences served as secondary and tertiary endpoints, respectively. The mean time of follow-up was about 2 years.

Researchers found no statistical differences between the groups in terms of mortality, stroke, or second AMI. Despite the unexpected results, investigators say the data show important benefits from aggressive metabolic management following AMI in patients with diabetes.

POSTER PRESENTATION

Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin 30 (BHI30): data from the REACH study. McNally P, Fitch M, Nelson G

This multi-centre, double-blind, randomised, two-period crossover study investigated the rates of nocturnal hypoglycaemia in patients with type 2 diabetes taking either NovoMix[R] 30 or biphasic human insulin 30 (BHI30). Continuous blood glucose monitoring (CBGM) was used to follow changes in the patients' blood glucose concentration.

During an 8-week run-in period, insulin doses were titrated until patients achieved target pre-breakfast and pre-dinner blood glucose concentrations of 5-7 mmol/L. Patients who achieved an Hb[A.sub.1c] level of 6.5-8.5% (n=145) at the end of the run-in period were randomly assigned to receive twice-daily injections of either NovoMix[R] 30 or BHI30 for a 16-week treatment period. At this point, patients were then switched to the alternative insulin for a further 16-week period.

The frequency of blood glucose readings <3.5 mmol/L was found to be lower when patients were treated with NovoMix[R] 30 compared to when they were taking BHI30, although this difference was not statistically significant (3.8% versus 4.4%, respectively; p=0.067). However, the mean frequency of nocturnal glucose concentrations <3.5 mmol/L was found to be statistically significantly lower during treatment with NovoMix[R] 30 compared with BHI30 (6.3% versus 7.8%; p=0.020). This statistically significant trend was also seen when considering nocturnal glucose readings <2.5 mmol/L.

PLENARY LECTURE

Beta-cell function in type 2 diabetes--the natural history of insulin secretion in type 2 diabetes. Matthews D

In modulating beta-cell function, the aim of the ideal agent would be to augment insulin secretion without the associated decline in beta-cell function. To date, no agents have been found which successfully achieve this. The co-efficient of failure suggests that glibenclamide may cause faster decline than chlorpropamide so not all agents have the same effect; the hunt is on for therapies which will combine the lowering of glycaemia with the preservation or augmentation of beta-cell function.

The therapeutics of insulin secretion have expanded rapidly in the last decade. A better understanding of the secretory mechanisms has resulted in a slightly stronger grasp of both the heterogeneity and the phenotypic variance of a variety of subtypes of diabetes. Modulating the GLP-1 axis is a useful therapeutic intervention and there is some hope that beta-cell failure can be slowed or even reversed.

COPYRIGHT 2004 S.B. Communications
COPYRIGHT 2004 Gale Group

Return to Chlorpropamide
Home Contact Resources Exchange Links ebay